Roche arthritis drug “breakthrough”

The results of a fifth phase III study into Roche’s Actemra (tocilizumab) show more signs it is an “important breakthrough” in the treatment of rheumatoid arthritis, the company says.

Findings appeared to show that the drug can prevent structural damage to joints in patients with arthritis, which is an important measure of how effective a drug is.

Patients who took the drug also found their physical function improves after 12 months of therapy and led them to a better quality of life.

The trial used a combination of Actemra and common arthritis drug methotrexate (MTX) and structural damage was seen to be prevented, compared to that in patients who used MTX alone.

William M. Burns, chief executive of Roche pharmaceuticals division, said: “By demonstrating an inhibition of joint damage and improving physical function, Actemra not only positively impacts the disease, but also helps patients to improve the quality of their lives.”

Last month the company announced its first quarter in 2008 revealed healthy growth.